Today, the term ‘undruggable’ is being redefined. Advances in membrane protein solubilization, allosteric modulation, and therapeutic viral vectors have led to proof that these targets can be tackled. Read more

Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise binders against a target antigen. However, emerging synthetic antibody library technologies now allow scientists to bypass animal immunization by using in silico designed vast libraries of human or humanized antibody fragments.

Isogenica, a specialist in synthetic VHH antibody discovery, was recognised in the Ones2Watch category for its scientific credibility and commercial momentum.

Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development timelines, and costly manufacturing. In a field where time is critical and healthcare budgets are under increasing pressure, these constraints can hold back promising innovations. Read the article.

Conventional immunization-based discovery techniques frequently result in overlapping sequences with intellectual property (IP) concerns, due to the high number of antibody sequences already patented. These limitations can restrict opportunities for development, increase legal uncertainty, and reduce commercial viability.

This case study delves into the development of anti-LRP6 VHH inhibitors that overcome these challenges. Isogenica’s VHH technology offers hope for more effective therapies targeting Wnt-related cancers.